Rafferty Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.8M | Sell |
356,169
-242,251
| -40% | -$1.23M | 0.01% | 627 |
|
|
2025
Q1 | $3.17M | Buy |
598,420
+2,948
| +0.5% | +$15.6K | 0.01% | 468 |
|
|
2024
Q4 | $4.03M | Sell |
595,472
-80,319
| -12% | -$543K | 0.01% | 456 |
|
|
2024
Q3 | $4.45M | Buy |
675,791
+231,547
| +52% | +$1.53M | 0.02% | 445 |
|
|
2024
Q2 | $3.33M | Sell |
444,244
-445,995
| -50% | -$3.34M | 0.01% | 502 |
|
|
2024
Q1 | $8.88M | Sell |
890,239
-199,934
| -18% | -$1.99M | 0.03% | 311 |
|
|
2023
Q4 | $10.7M | Sell |
1,090,173
-14,353
| -1% | -$142K | 0.05% | 255 |
|
|
2023
Q3 | $8.45M | Buy |
1,104,526
+784,113
| +245% | +$6M | 0.05% | 267 |
|
|
2023
Q2 | $2.39M | Sell |
320,413
-129,569
| -29% | -$968K | 0.01% | 598 |
|
|
2023
Q1 | $3M | Sell |
449,982
-146,085
| -25% | -$974K | 0.02% | 511 |
|
|
2022
Q4 | $4.6M | Buy |
596,067
+423,541
| +245% | +$3.27M | 0.04% | 387 |
|
|
2022
Q3 | $1.84M | Buy |
172,526
+35,900
| +26% | +$382K | 0.02% | 527 |
|
|
2022
Q2 | $1.11M | Buy |
136,626
+32,977
| +32% | +$268K | 0.01% | 613 |
|
|
2022
Q1 | $742K | Sell |
103,649
-291,485
| -74% | -$2.09M | ﹤0.01% | 845 |
|
|
2021
Q4 | $6.77M | Buy |
395,134
+327,113
| +481% | +$5.6M | 0.04% | 268 |
|
|
2021
Q3 | $1.57M | Buy |
+68,021
| New | +$1.57M | 0.01% | 696 |
|